Abstract
Management options for bloodborne diseases depend on prevalence (herd level and geographic), disease stage and production class. Opportunities to manage disease can be classified according to disease stage. Newer studies show that, in contrast to older studies, there is not currently a known legal way to clear animals of anaplasmosis. The only currently labeled products for treatment of acute clinical anaplasmosis are injectable oxytetracyclines. For a time, an enrofloxacin product (Baytril-CA) was marketed with a label for treatment of anaplasmosis, but the conditional approval application has been withdrawn. Opportunities for leukosis management are limited to exposure control as there are no effective treatments for animals in the clinical stage and no effective methods to clear infected non-clinical animals. Due to the relatively high prevalence in beef herds, a strict test-and-cull strategy is not practical. Instead identifying animals with high pre-viral load who are most infectious provides an option to decrease disease levels with reasonable economics at the farm level. More research is necessary to fully quantify production effects for carrier animals of both bovine leukosis and anaplasmosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Association of Bovine Practitioners Conference Proceedings
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
